126 related articles for article (PubMed ID: 382435)
21. Thrombogenicity of a factor IX concentrate quantitated in a canine model.
MacGregor IR; Ferguson JF; Dawes J; McLaughlin L; Prowse CV
Blood Coagul Fibrinolysis; 1990; 1(1):23-30. PubMed ID: 2102787
[TBL] [Abstract][Full Text] [Related]
22. Relationship between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC and various non-thromboembolic diseases.
Mombelli G; Monotti R; Haeberli A; Straub PW
Thromb Haemost; 1987 Aug; 58(2):758-63. PubMed ID: 3672428
[TBL] [Abstract][Full Text] [Related]
23. Studies of coagulation and platelet functions in heparin-free hemodialysis.
Ivanovich P; Xu CG; Kwaan HC; Hathiwala S
Nephron; 1983; 33(2):116-20. PubMed ID: 6835458
[TBL] [Abstract][Full Text] [Related]
24. [Hemostatic mechanisms and malignant tumors].
Kase F; Pospísil J; Hlousková D
Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(6):809-30. PubMed ID: 2419210
[TBL] [Abstract][Full Text] [Related]
25. [Interactions of blood platelets and erythrocytes with fibrinogen and fibrin].
Niewiarowski S; Stewart GG
Pol Arch Med Wewn; 1978 Jan; 59(1):67-78. PubMed ID: 652583
[No Abstract] [Full Text] [Related]
26. Fibrinopeptide A release from intraplatelet fibrinogen is related to thrombin platelet activation.
Vila V; Martinez-Sales V; Réganon E; Aznar J
Thromb Res; 1997 May; 86(3):263-9. PubMed ID: 9175247
[No Abstract] [Full Text] [Related]
27. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors.
Weitz JI; Leslie B; Hudoba M
Circulation; 1998 Feb; 97(6):544-52. PubMed ID: 9494024
[TBL] [Abstract][Full Text] [Related]
28. [Diagnostic significance of proteolytic breakdown products of fibrinogen and fibrin].
Heene DL; Genth K
Internist (Berl); 1984 Feb; 25(2):93-101. PubMed ID: 6231262
[No Abstract] [Full Text] [Related]
29. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
[TBL] [Abstract][Full Text] [Related]
30. [Fibrinogen metabolism and plasma fibrinopeptide A in disseminated neoplasms].
Mombelli G; Roux A; Hofmann V; Straub PW
Schweiz Med Wochenschr; 1979 Dec; 109(47):1901. PubMed ID: 531571
[TBL] [Abstract][Full Text] [Related]
31. The haemostatic mechanisms in pre-eclampsia.
Howie PW
Clin Obstet Gynaecol; 1977 Dec; 4(3):595-611. PubMed ID: 340109
[No Abstract] [Full Text] [Related]
32. Assay of heparin in plasma using a chromogenic substrate and its clinical applications.
Hasegawa H; Oguma Y; Takei H; Seya T; Yamauchi M; Murakoshi T; Nagata H; Murao M
Jpn Heart J; 1980 May; 21(3):367-80. PubMed ID: 7401317
[TBL] [Abstract][Full Text] [Related]
33. Properties of fibrinogen cleaved by Jararhagin, a metalloproteinase from the venom of Bothrops jararaca.
Kamiguti AS; Slupsky JR; Zuzel M; Hay CR
Thromb Haemost; 1994 Aug; 72(2):244-9. PubMed ID: 7831660
[TBL] [Abstract][Full Text] [Related]
34. Coagulofibrinolysis during heparin-coated cardiopulmonary bypass with reduced heparinization.
Kumano H; Suehiro S; Hattori K; Shibata T; Sasaki Y; Hosono M; Kinoshita H
Ann Thorac Surg; 1999 Oct; 68(4):1252-6. PubMed ID: 10543488
[TBL] [Abstract][Full Text] [Related]
35. Effects of long-term treatment with warfarin on fibrinogen, FPA, TAT, and D-dimer in patients with coronary artery disease.
Eritsland J; Seljeflot I; Arnesen H; Smith P; Westvik AB
Thromb Res; 1992 Apr; 66(1):55-60. PubMed ID: 1412183
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of fibrinopeptide A generation tests in experimental and clinical studies with low molecular weight heparin fractions.
Emanuele RM; Fareed J; Walenga JM; Hoppensteadt DA; Baker WH
Semin Thromb Hemost; 1985 Apr; 11(2):121-8. PubMed ID: 4035363
[TBL] [Abstract][Full Text] [Related]
37. Elevated fibrin(ogen) degradation products in the adult respiratory distress syndrome.
Haynes JB; Hyers TM; Giclas PC; Franks JJ; Petty TL
Am Rev Respir Dis; 1980 Dec; 122(6):841-7. PubMed ID: 6450559
[TBL] [Abstract][Full Text] [Related]
38. Requirements for thromboresistance of surface-heparinized materials.
Olsson P; Larm O; Larsson R; Lins LE; Nilsson E; Swedenborg J
Ann N Y Acad Sci; 1983; 416():525-37. PubMed ID: 6145383
[No Abstract] [Full Text] [Related]
39. Radioimmunoassays of human fibrinopeptides A and B.
Budzyński AZ; Marder VJ
Pol Arch Med Wewn; 1978 Jan; 59(1):43-8. PubMed ID: 349523
[No Abstract] [Full Text] [Related]
40. Kinetic characterization of hemostasis in thermal injury.
Simon TL; Curreri PW; Harker LA
J Lab Clin Med; 1977 Apr; 89(4):702-11. PubMed ID: 845474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
